KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $1.6 billion.

  • Regeneron Pharmaceuticals' Other Non-Current Liabilities rose 20.61% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 20.61%. This contributed to the annual value of $1.6 billion for FY2024, which is 83.98% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Other Non-Current Liabilities of $1.6 billion as of FY2024, which was up 83.98% from $854.1 million recorded in FY2023.
  • Regeneron Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $1.6 billion during FY2024, with a 5-year trough of $638.0 million in FY2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $854.1 million (2023), whereas its average is $1.0 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Other Non-Current Liabilities decreased by 6.20% in 2022, and later surged by 83.98% in 2024.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Other Non-Current Liabilities stood at $687.1 million in 2020, then dropped by 1.00% to $680.2 million in 2021, then decreased by 6.20% to $638.0 million in 2022, then skyrocketed by 33.87% to $854.1 million in 2023, then soared by 83.98% to $1.6 billion in 2024.